Palbociclib Hydrochloride is a selective CDK4/6 inhibitor used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, typically in combination with endocrine therapy. As… Read more
Palbociclib Hydrochloride is a selective CDK4/6 inhibitor used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, typically in combination with endocrine therapy. As a potent kinase inhibitor, its clinical application requires rigorous quality control and precise analytical characterization throughout development and manufacturing. This category provides access to essential Palbociclib Hydrochloride reference standards, including the active pharmaceutical ingredient, pharmacopeial and non-pharmacopeial impurities, and relevant metabolites. These compounds are critical for laboratory professionals conducting impurity profiling, method validation, and stability testing. Researchers utilize stable isotope labelled versions of these molecules as internal standards in mass spectrometry-based assays, ensuring high accuracy and sensitivity when quantifying drug levels in complex biological matrices or monitoring degradation products during shelf-life studies.